Skip to content

Laparoscopic Versus Open Repair of Peptic Ulcer Perforation

Comparison Between Laparoscopic and Open Repair of Perforated Gastroduodenal Peptic Ulcer

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04447170
Acronym
LOREPUP
Enrollment
200
Registered
2020-06-25
Start date
2017-01-01
Completion date
2022-04-01
Last updated
2021-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emergencies, Peptic Ulcer Perforation, Surgery

Keywords

Peptic ulcer perforation, Laparoscopy

Brief summary

Although laparoscopic repair (LR) of perforated peptic ulcers (PPUs) has long been accepted, clinical evidence comparing LR versus open repair (OR) remains lacking. The aim of this study is to evaluate the feasibility, safety and outcome of laparoscopic gastric repair and compare it with the outcome open repair by relying on a propensity score matching statistical technique

Detailed description

Despite the evolution of medical management of Gastroduodenal Peptic Ulcer (GPU), complications like bleeding and perforation are still not uncommon in clinical practice. According to the literature in average, 2-14% of peptic ulcers result in perforation, most 215 commonly occurring in females over the age of 60 and chronic NSAID, alcohol or tobacco users. Management of perforated peptic ulcer entails resuscitation, pharmacotherapy and surgery. Traditionally, suture with or without omental patch has been considered the 'gold standard' and still is. It is associated with shorter length of stay, lower transfusion needs and has lower morbidity as compared to gastrectomy. In 1992, it has been proposed that laparoscopy should be routinely considered in the management of perforated duodenal ulcer. Nowadays due to the advances in laparoscopic technique, many publications suggest that laparoscopic repair of perforated peptic ulcers could be a superior choice to open repair. These is linked with the advantages of laparoscopic surgery over open surgery such as reduced postoperative pain, lower wound infection rate, decreased length of hospital stay, and earlier functional recovery

Interventions

PROCEDURESimple repair or Graham technique

Simple suture with or without omental protective patch

Sponsors

Gianluca Costa
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients surgically treated for benign peptic ulcer perforation

Exclusion criteria

* Age \< 18 years * Pregnant and breastfeeding women * Malignant ulcer perforation * Gastric resection * Diagnostic laparoscopy/laparotomy with no further surgical procedures performed

Design outcomes

Primary

MeasureTime frameDescription
30-day Mortality Rate18 months
30-day Morbidity Rate18 monthsMorbidity defined by mean of the most used classification scoring system

Secondary

MeasureTime frameDescription
Calculation of Mannheim Peritonitis Index18 monthsCalculation and evaluation of its predictive value for morbidity and mortality
Calculation of Shock index18 monthsCalculation and evaluation of its predictive value for morbidity and mortality
Conversion rate18 monthsDefined when a procedure was attempted via the minimally invasive approach but required an open incision to be completed
Operative time18 monthsThe duration time of surgical step from in The duration of the surgical procedure
Calculation of Charlson Age-Comorbidity Index (CACI)18 monthsCalculation and evaluation of its predictive value for morbidity and mortality
Calculation of Age-related shock index18 monthsCalculation and evaluation of its predictive value for morbidity and mortality
Calculation of Boey index18 monthsCalculation and evaluation of its predictive value for morbidity and mortality

Countries

Italy

Contacts

Primary ContactGianluca Costa, MD, PhD
gianlucacostaphd@gmail.com00393921119067
Backup ContactPietro Fransvea, MD
Pietro.fransvea@gmail.com00393289275731

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026